nach oben

Erschienen in:

01.06.2015

Targeting roles of inflammatory microenvironment in lung cancer and metastasis

verfasst von: Lin Shi, Lingyan Wang, Jiayan Hou, Bijun Zhu, Zhihui Min, Miaomiao Zhang, Dongli Song, Yunfeng Cheng, Xiangdong Wang

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Inflammatory cells and mediators are essential components in tumor microenvironment and play decisive roles in the initiation, proliferation, survival, promotion, invasion, or metastasis of lung cancer. Clinical and epidemiologic studies suggested a strong association between inflammation and lung cancer and an influence of immune surveillances and tumor responses to chemotherapeutic drugs, although roles of inflammation in lung cancer remain unclear. The present review outlined roles of inflammation in lung cancer, with particular focus on inflammatory components, types, biomarkers, or principal mechanisms by which the inflammation contributes to the development of lung cancer. The cancer-associated inflammatory cells (CICs) should be furthermore defined and include cancer-specific and interacted cells with inflammatory or inflammation-like characteristics, e.g., innate or adaptive immune cells and cancer tissue cells. We also discuss targeting potentials of inflammation in the prevention and treatment of lung cancer. The diversity of cancer-related inflammatory microenvironment is instrumental to design novel therapeutic approaches for lung cancer.

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454(7203), 436–444.PubMed

Kruse, J. L., & Strouse, T. B. (2015). Sick and tired: mood, fatigue, and inflammation in cancer. Current Psychiatry Reports, 17(3), 555.PubMed

Balkwill, F. R., & Mantovani, A. (2012). Cancer-related inflammation: common themes and therapeutic opportunities. Seminars in Cancer Biology, 22(1), 33–40.PubMed

Bremnes, R. M., Al-Shibli, K., Donnem, T., Sirera, R., Al-Saad, S., Andersen, S., et al. (2011). The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. Journal of Thoracic Oncology, 6(4), 824–833.PubMed

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.PubMed

Araujo, A., Ribeiro, R., Azevedo, I., Coelho, A., Soares, M., Sousa, B., et al. (2007). Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer—a review of the literature. The Oncologist, 12(2), 201–210.PubMed

Wu, K., House, L., Liu, W., & Cho, W. C. (2012). Personalized targeted therapy for lung cancer. International Journal of Molecular Sciences, 13(9), 11471–11496.PubMedCentralPubMed

Ferlay, J., Parkin, D. M., & Steliarova-Foucher, E. (2010). Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer, 46(4), 765–781.PubMed

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 87–108.

10.

Xu, Y., Zhang, J., Han, J., Pan, X., Cao, Y., Guo, H., et al. (2012). Curcumin inhibits tumor proliferation induced by neutrophil elastase through the upregulation of alpha1-antitrypsin in lung cancer. Molecular Oncology, 6(4), 405–417.PubMed

11.

Engels, E. A. (2008). Inflammation in the development of lung cancer: epidemiological evidence. Expert Review of Anticancer Therapy, 8(4), 605–615.PubMed

12.

de-Torres, J. P., Wilson, D. O., Sanchez-Salcedo, P., Weissfeld, J. L., Berto, J., Campo, A., et al. (2015). Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. American Journal of Respiratory and Critical Care Medicine, 191(3), 285–291.PubMed

13.

Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008). Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science, 320(5876), 674–677.PubMedCentralPubMed

14.

Barbieri, S. S., & Weksler, B. B. (2007). Tobacco smoke cooperates with interleukin-1beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. The FASEB Journal, 21(8), 1831–1843.PubMed

15.

de Visser, K. E., Eichten, A., & Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer, 6(1), 24–37.PubMed

16.

Zhang, M., He, Y., Sun, X., Li, Q., Wang, W., Zhao, A., et al. (2014). A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. Journal of Ovarian Research, 7, 19.PubMedCentralPubMed

17.

Schioppa, T., Moore, R., Thompson, R. G., Rosser, E. C., Kulbe, H., Nedospasov, S., et al. (2011). B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 108(26), 10662–10667.PubMedCentralPubMed

18.

Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., et al. (2010). FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell, 17(2), 121–134.PubMedCentralPubMed

19.

DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., et al. (2009). CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 16(2), 91–102.PubMedCentralPubMed

20.

Bygd, H. C., Forsmark, K. D., & Bratlie, K. M. (2014). The significance of macrophage phenotype in cancer and biomaterials. Clinical and Translational Medicine, 3, 62.

21.

Barriere, G., Fici, P., Gallerani, G., Fabbri, F., & Rigaud, M. (2015). Epithelial mesenchymal transition: a double-edged sword. Clinical and Translational Medicine, 4, 14.PubMedCentralPubMed

22.

Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., et al. (2010). Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science, 330(6005), 827–830.PubMed

23.

Luo, H., Tu, G., Liu, Z., & Liu, M. (2015). Cancer-associated fibroblasts: a multifaceted driver of breast cancer progression. Cancer Letters, 361(2), 155–163.PubMed

24.

Wermuth, P. J., & Jimenez, S. A. (2015). The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clinical and Translational Medicine, 4, 2.PubMedCentralPubMed

25.

Lin, G. N., Peng, J. W., Liu, P. P., Liu, D. Y., Xiao, J. J., & Chen, X. Q. (2014). Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment. Asia-Pacific Journal of Clinical Oncology. doi:10.1111/ajco.12273.

26.

Gregory, A. D., & Houghton, A. M. (2011). Tumor-associated neutrophils: new targets for cancer therapy. Cancer Research, 71(7), 2411–2416.PubMed

27.

Pandey, J. P. (2011). Prognostic immune markers in non-small cell lung cancer—letter. Clinical Cancer Research, 17(24), 7835–7836.PubMed

28.

Ammirante, M., Luo, J. L., Grivennikov, S., Nedospasov, S., & Karin, M. (2010). B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature, 464(7286), 302–305.PubMedCentralPubMed

29.

Zhao, P., Bu, X., Wei, X., Sun, W., Xie, X., Li, C., et al. (2015). Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer. International Immunopharmacology, 25(2), 450–456.PubMed

30.

Dyduch, G., Kaczmarczyk, K., & Okon, K. (2012). Mast cells and cancer: enemies or allies? Polish Journal of Pathology, 63(1), 1–7.PubMed

31.

Tomassetti, S., Gurioli, C., Ryu, J. H., Decker, P. A., Ravaglia, C., Tantalocco, P., et al. (2015). The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest, 147(1), 157–164.PubMed

32.

Lin, W. W., & Karin, M. (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. Journal of Clinical Investigation, 117(5), 1175–1183.PubMedCentralPubMed

33.

Aggarwal, B. B. (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology, 3(9), 745–756.PubMed

34.

Gregorc, V., De Braud, F. G., De Pas, T. M., Scalamogna, R., Citterio, G., Milani, A., et al. (2011). Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clinical Cancer Research, 17(7), 1964–1972.PubMed

35.

Kim, V., Rogers, T. J., & Criner, G. J. (2008). New concepts in the pathobiology of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society, 5(4), 478–485.PubMedCentralPubMed

36.

Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., et al. (2015). Targeting the TGFbeta pathway for cancer therapy. Pharmacology and Therapeutics, 147, 22–31.PubMed

37.

O’Connor, J. W., & Gomez, E. W. (2014). Biomechanics of TGFβ-induced epithelial-mesenchymal transition: implications for fibrosis and cancer. Clinical and Translational Medicine, 3, 23.PubMedCentralPubMed

38.

Hasan, M., Neumann, B., Haupeltshofer, S., Stahlke, S., Claudio Fantini, M., Angstwurm, K., et al. (2015). Activation of TGF-beta-induced non-Smad signaling pathways during Th17 differentiation. Immunology and Cell Biology. doi:10.1038/icb.2015.21.

39.

Heerboth, S., Housman, G., Leary, M., Longacre, M., Byler, S., Lapinska, K., Willbanks, A., & Sarkar, S. (2015). EMT and tumor metastasis. Clinical and Translational Medicine, 4, 6.PubMedCentralPubMed

40.

Risolino, M., Mandia, N., Iavarone, F., Dardaei, L., Longobardi, E., Fernandez, S., et al. (2014). Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-beta-SMAD3 pathway in non-small cell lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 111(36), 3775–3784.

41.

Ochoa, C. E., Mirabolfathinejad, S. G., Ruiz, V. A., Evans, S. E., Gagea, M., Evans, C. M., et al. (2011). Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prevention Research (Philadelphia, Pa.), 4(1), 51–64.

42.

Naugler, W. E., & Karin, M. (2008). The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends in Molecular Medicine, 14(3), 109–119.PubMed

43.

Uskudar Teke, H., Gunduz, E., Akay, O. M., Bal, C., & Gulbas, Z. (2015). Are the high serum interleukin-6 and vascular endothelial growth factor levels useful prognostic markers in aggressive non-Hodgkin lymphoma patients? Turkish Journal of Haematology, 32(1), 21–28.PubMed

44.

Song, L., Rawal, B., Nemeth, J. A., & Haura, E. B. (2011). JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Molecular Cancer Therapeutics, 10(3), 481–494.PubMedCentralPubMed

45.

Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., et al. (2010). TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(35), 15535–15540.PubMedCentralPubMed

46.

Frantzi, M., Bhat, A., & Latosinska, A. (2014). Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clinical and Translational Medicine, 3, 7.PubMedCentralPubMed

47.

Colasante, A., Mascetra, N., Brunetti, M., Lattanzio, G., Diodoro, M., Caltagirone, S., et al. (1997). Transforming growth factor beta 1, interleukin-8 and interleukin-1, in non-small-cell lung tumors. American Journal of Respiratory and Critical Care Medicine, 156(3 Pt 1), 968–973.PubMed

48.

Swindell, W. R., Sarkar, M. K., Stuart, P. E., Voorhees, J. J., Elder, J. T., Johnston, A., & Gudjonsson, J. E. (2015). Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites. Clinical and Translational Medicine, 4, 13.PubMedCentralPubMed

49.

Erez, N., Truitt, M., Olson, P., Arron, S. T., & Hanahan, D. (2010). Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell, 17(2), 135–147.PubMed

50.

Camnitz, W., Burdick, M. D., Strieter, R. M., Mehrad, B., & Keeley, E. C. (2012). Dose-dependent effect of statin therapy on circulating CXCL12 levels in patients with hyperlipidemia. Clinical and Translational Medicine, 1, 23.PubMedCentralPubMed

51.

Burger, J. A., & Stewart, D. J. (2009). CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opinion on Investigational Drugs, 18(4), 481–490.PubMed

52.

Pfeiffer, M., Hartmann, T. N., Leick, M., Catusse, J., Schmitt-Graeff, A., & Burger, M. (2009). Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. British Journal of Cancer, 100(12), 1949–1956.PubMedCentralPubMed

53.

Minamiya, Y., Saito, H., Takahashi, N., Ito, M., Imai, K., Ono, T., et al. (2010). Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Lung Cancer, 68(3), 466–471.PubMed

54.

Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L. P., et al. (2011). Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature, 475(7355), 226–230.PubMed

55.

Danilova, E., Skrindo, I., Gran, E., Hales, B. J., Smith, W. A., Jahnsen, J., Johansen, F. E., Jahnsen, F. L., & Baekkevold, E. S. (2015). A role for CCL28-CCR3 in T-cell homing to the human upper airway mucosa. Mucosal Immunology, 8(1), 107–114.PubMed

56.

Qian, B. Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., et al. (2011). CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 475(7355), 222–225.PubMedCentralPubMed

57.

Targosz, A., Brzozowski, T., Pierzchalski, P., Szczyrk, U., Ptak-Belowska, A., Konturek, S. J., et al. (2012). Helicobacter pylori promotes apoptosis, activates cyclooxygenase (COX)-2 and inhibits heat shock protein HSP70 in gastric cancer epithelial cells. Inflammation Research, 61(9), 955–966.PubMedCentralPubMed

58.

Wu, S., Rhee, K. J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H. R., et al. (2009). A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Medicine, 15(9), 1016–1022.PubMedCentralPubMed

59.

Hessol, N. A., Martinez-Maza, O., Levine, A. M., Morris, A., Margolick, J. B., Cohen, M. H., et al. (2015). Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS. PMID: 25888645

60.

Cimato, T. R., & Palka, B. A. (2014). Fractalkine (CX3CL1), GM-CSF and VEGF-a levels are reduced by statins in adult patients. Clinical and Translational Medicine, 3, 14.PubMedCentralPubMed

61.

Graves, C. A., Abboodi, F. F., Tomar, S., Wells, J., & Pirisi, L. (2014). The translational significance of epithelial-mesenchymal transition in head and neck cancer. Clinical and Translational Medicine, 3, 39.

62.

Zhang, Y., Wang, L., Zhang, M., Jin, M., Bai, C., & Wang, X. (2012). Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway. Journal of Cellular Physiology, 227(1), 35–43.PubMed

63.

Zong, W. X., & Thompson, C. B. (2006). Necrotic death as a cell fate. Genes and Development, 20(1), 1–15.PubMed

64.

Letzkus, M., Luesink, E., Starck-Schwertz, S., Bigaud, M., Mirza, F., Hartmann, N., et al. (2014). Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trials. Clinical and Translational Medicine, 3, 36.PubMedCentralPubMed

65.

Spitz, M. R., Gorlov, I. P., Amos, C. I., Dong, Q., Chen, W., Etzel, C. J., et al. (2011). Variants in inflammation genes are implicated in risk of lung cancer in never smokers exposed to second-hand smoke. Cancer Discovery, 1(5), 420–429.PubMedCentralPubMed

66.

Stueckle, T. A., Lu, Y., Davis, M. E., Wang, L., Jiang, B. H., Holaskova, I., et al. (2012). Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicology and Applied Pharmacology, 261(2), 204–216.PubMedCentralPubMed

67.

Landvik, N. E., Tekpli, X., Anmarkrud, K. H., Haugen, A., & Zienolddiny, S. (2012). Molecular characterization of a cancer-related single nucleotide polymorphism in the pro-inflammatory interleukin-1B gene. Molecular Carcinogenesis, 51(Suppl 1), 168–175.

68.

Yan, B., Wang, H., Rabbani, Z. N., Zhao, Y., Li, W., Yuan, Y., et al. (2006). Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Research, 66(24), 11565–11570.PubMed

69.

Karabela, S. P., Kairi, C. A., Magkouta, S., Psallidas, I., Moschos, C., Stathopoulos, I., et al. (2011). Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in mice. Neoplasia, 13(12), 1143–1151.PubMedCentralPubMed

70.

Verhelst, K., Verstrepen, L., Carpentier, I., & Beyaert, R. (2013). IkappaB kinase epsilon (IKKepsilon): a therapeutic target in inflammation and cancer. Biochemical Pharmacology, 85(7), 873–880.PubMed

71.

Karin, M. (2008). The IkappaB kinase—a bridge between inflammation and cancer. Cell Research, 18(3), 334–342.PubMed

72.

Azevedo, A., Cunha, V., Teixeira, A. L., & Medeiros, R. (2011). IL6/IL6R as a potential key signaling pathway in prostate cancer development. World Journal of Clinical Oncology, 2(12), 384–396.PubMedCentralPubMed

73.

Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limon, P. (2010). The polarization of immune cells in the tumour environment by TGFbeta. Nature Reviews Immunology, 10(8), 554–567.PubMed

74.

Shih, C. M., Lee, Y. L., Chiou, H. L., Hsu, W. F., Chen, W. E., Chou, M. C., et al. (2005). The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer, 50(3), 291–297.PubMed

75.

Montuenga, L. M., & Pio, R. (2007). Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. European Respiratory Journal, 30(4), 608–610.PubMed

76.

Fini, M. A., Elias, A., Johnson, R. J., Richard, M., & Wright, R. M. (2012). Contribution of uric acid to cancer risk, recurrence, and mortality. Clinical and Translational Medicine, 1, 16.PubMedCentralPubMed

77.

Gurda, G. T., Zhang, L., Wang, Y., Chen, L., Geddes, S., Cho, W. C., et al. (2015). Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases. Clinical and Translational Medicine, 4, 16.PubMedCentralPubMed

78.

Ganguly, R., Mohyeldin, A., Thiel, J., Kornblum, H. I., Beullen, M., & Nakano, I. (2015). MELK—a conserved kinase: functions, signaling, cancer, and controversy. Clinical and Translational Medicine, 4, 11.PubMedCentralPubMed

79.

Viger, L., Denis, F., Rosalie, M., & Letellier, C. (2014). A cancer model for the angiogenic switch. Journal of Theoretical Biology, 360, 21–33.PubMed

80.

Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., et al. (2008). NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature, 453(7196), 807–811.PubMedCentralPubMed

81.

Wang, J. Q., & Wu, K. J. (2015). Epigenetic regulation of epithelial-mesenchymal transition by hypoxia in cancer: targets and therapy. Current Pharmaceutical Design, 21(10), 1272–1278.PubMed

82.

Gori, B., Ricciardi, S., Fulvi, A., Del Signore, E., & de Marinis, F. (2012). New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment. Future Oncology, 8(5), 559–573.PubMed

83.

Qian, Q., Shi, X., Lei, Z., Zhan, L., Liu, R. Y., Zhao, J., et al. (2014). Methylated +58CpG site decreases DCN mRNA expression and enhances TGF-beta/Smad signaling in NSCLC cells with high metastatic potential. International Journal of Oncology, 44(3), 874–882.PubMed

84.

Polyak, K., & Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer, 9(4), 265–273.PubMed

85.

Merikallio, H., Turpeenniemi-Hujanen, T., Paakko, P., Makitaro, R., Riitta, K., Salo, S., et al. (2012). Snail promotes an invasive phenotype in lung carcinoma. Respiratory Research, 13, 104.PubMedCentralPubMed

86.

Gonzalez-Arriaga, P., Pascual, T., Garcia-Alvarez, A., Fernandez-Somoano, A., Lopez-Cima, M. F., & Tardon, A. (2012). Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer, 12, 121.PubMedCentralPubMed

87.

Roy, R., Yang, J., & Moses, M. A. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of Clinical Oncology, 27(31), 5287–5297.PubMedCentralPubMed

88.

Li, W., Li, S., Deng, L., Yang, S., Li, M., Long, S., et al. (2015). Decreased MT1-MMP in gastric cancer suppressed cell migration and invasion via regulating MMPs and EMT. Tumour Biology. doi:10.1007/s13277-015-3381-7.

89.

Atkinson, J. J., & Senior, R. M. (2003). Matrix metalloproteinase-9 in lung remodeling. American Journal of Respiratory Cell and Molecular Biology, 28(1), 12–24.PubMed

90.

Gilles, C., Bassuk, J. A., Pulyaeva, H., Sage, E. H., Foidart, J. M., & Thompson, E. W. (1998). SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Research, 58(23), 5529–5536.PubMed

91.

Yu, H., Kortylewski, M., & Pardoll, D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Reviews Immunology, 7(1), 41–51.PubMed

92.

Zeni, E., Mazzetti, L., Miotto, D., Lo Cascio, N., Maestrelli, P., Querzoli, P., et al. (2007). Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. European Respiratory Journal, 30(4), 627–632.PubMed

93.

Hatanaka, H., Abe, Y., Kamiya, T., Morino, F., Nagata, J., Tokunaga, T., et al. (2000). Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Annals of Oncology, 11(7), 815–819.PubMed

94.

De Vita, F., Orditura, M., Galizia, G., Romano, C., Roscigno, A., Lieto, E., et al. (2000). Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest, 117(2), 365–373.PubMed

95.

Pine, S. R., Mechanic, L. E., Enewold, L., Chaturvedi, A. K., Katki, H. A., Zheng, Y. L., et al. (2011). Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. Journal of the National Cancer Institute, 103(14), 1112–1122.PubMedCentralPubMed

96.

De Vita, F., Orditura, M., Auriemma, A., Infusino, S., Roscigno, A., & Catalano, G. (1998). Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncology Reports, 5(3), 649–652.PubMed

97.

Chang, K. T., Huang, C. Y., Tsai, C. M., Chiu, C. H., & Lok, Y. Y. (2005). Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer. American Journal of Physiology - Lung Cellular and Molecular Physiology, 289(3), 438–445.

98.

Jumper, C., Cobos, E., & Lox, C. (2004). Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respiratory Medicine, 98(2), 173–177.PubMed

99.

Liu, D., Nakano, J., Ishikawa, S., Yokomise, H., Ueno, M., Kadota, K., et al. (2007). Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer, 58(3), 384–391.PubMed

100.

Lin, Y., Bai, L., Chen, W., & Xu, S. (2010). The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opinion on Therapeutic Targets, 14(1), 45–55.PubMedCentralPubMed

101.

Moran, C. J., Arenberg, D. A., Huang, C. C., Giordano, T. J., Thomas, D. G., Misek, D. E., et al. (2002). RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clinical Cancer Research, 8(12), 3803–3812.PubMed

102.

Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377(9759), 31–41.PubMed

103.

Jin, G. H., Hirano, T., & Murakami, M. (2008). Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation. International Immunology, 20(6), 783–789.PubMed

104.

Herbst, R. S. (2004). Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology, Biology, and Physics, 59(2 Suppl), 21–26.

105.

Heinrich, E. L., Walser, T. C., Krysan, K., Liclican, E. L., Grant, J. L., Rodriguez, N. L., et al. (2012). The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis. Cancer Microenvironment, 5(1), 5–18.PubMedCentralPubMed

106.

Sato, M., Shames, D. S., & Hasegawa, Y. (2012). Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology, 17(7), 1048–1059.PubMed

Titel: Targeting roles of inflammatory microenvironment in lung cancer and metastasis
verfasst von: Lin Shi
Lingyan Wang
Jiayan Hou
Bijun Zhu
Zhihui Min
Miaomiao Zhang
Dongli Song
Yunfeng Cheng
Xiangdong Wang
Publikationsdatum: 01.06.2015
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2/2015
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-015-9570-4

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Targeting roles of inflammatory microenvironment in lung cancer and metastasis

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Roles of CEACAM1 in cell communication and signaling of lung cancer and other diseases

New strategies to develop new medications for lung cancer and metastasis

Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer

Association of chromosome 19 to lung cancer genotypes and phenotypes

Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer

Global analyses of subtype- or stage-specific genes on chromosome 7 in patients with lung cancer

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie